Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While FOXO4-DRI acts as a senolytic in preclinical models by promoting apoptosis of senescent cells, improving tissue function and healthspan measures in aged animals38, Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880.
While FOXO4-DRI works as a D-retro-inverso peptide derived from a FOXO4 region that competes with endogenous FOXO4 for binding to p53, thereby releasing p53 to trigger apoptosis selectively in senescent cells38, Liraglutide is a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880.
FOXO4-DRI
FOXO4
Liraglutide
GCG
FOXO4-DRI and Liraglutide are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: FOXO4-DRI is more often discussed in the realm of Aging and longevity, whereas Liraglutide is more often associated with the realm of Metabolic and endocrine. Their biological logic is quite different: FOXO4-DRI is a protein interaction inhibitor, whereas Liraglutide is a receptor agonist and a hormone analog. FOXO4-DRI has a more synthetic design origin, while Liraglutide is closer to synthetic analog background and their development context also differs, with FOXO4-DRI in Preclinical development while Liraglutide is approved. FOXO4-DRI takes the form of a linear peptide, whereas Liraglutide is closer to a peptide conjugate, FOXO4-DRI carries retro-inverso isomerization features, while Liraglutide instead reflects palmitoylation changes; while their sequence patterns also diverge, with FOXO4-DRI showing protein-mimetic sequence features and Liraglutide showing alpha-helical domain features.